04:10am Vertex Pharmaceuticals Incorporated Receives Us Fda Approval for Expanded Use of Casgevy for Treatment of People Ages 2 Years and Older with Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia CI
03:55am Vertex Pharmaceuticals Says FDA Approves Expanded Use of Casgevy in Younger Children With Blood Disorders MT
07:59pm Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia BU
06:43pm US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two RE
07-01 Vertex Pharmaceuticals Gets FDA OK for Sickle Cell Disease Treatment in Young Children DJ
06-29 Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell 1000 Value Benchmark CI
06-28 Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 3000E Growth Benchmark CI
06-28 Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Growth Benchmark CI
06-28 Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Growth-Defensive Index CI
06-28 Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell 3000E Value Benchmark CI
06-28 Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell 3000 Value Benchmark CI
06-28 Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell 1000 Value-Defensive Index CI
06-28 Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell Top 200 Value Benchmark CI
06-28 Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell Top 200 Growth Benchmark CI
06-28 Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 3000 Growth Benchmark CI
06-17 Vertex Pharmaceuticals Insider Sold Shares Worth $1,827,900, According to a Recent SEC Filing MT
06-11 Vertex's Late-Stage Clinical Data of Casgevy Deliver Crisis-Free, Transfusion-Free Results in Kids With Blood Disorders MT
06-11 Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions BU
06-11 Vertex Pharmaceuticals Incorporated Presents New Data on Casgevy and Announces Additional Global Regulatory Submissions CI
06-10 Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 11:20 AM
06-09 Vertex Pharmaceuticals Insider Sold Shares Worth $785,250, According to a Recent SEC Filing MT
06-05 Vertex Pharmaceuticals Incorporated Presents New Data On ALYFTREK And TRIKAFTA At European Cystic Fibrosis Conference CI
06-05 Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference BU
06-03 Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 BU
06-02 Vertex Pharmaceuticals Insider Sold Shares Worth $888,300, According to a Recent SEC Filing MT
No results match your criteria
  1. Stock Market
  2. Stocks
  3. VRTX Stock
  4. News Vertex Pharmaceuticals Incorporated